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Abstract. 
Objectives: Up to 40% of women over 70 years with primary operable breast cancer in the UK are 
treated with Primary Endocrine Therapy (PET) as an alternative to surgery. A variety of factors are 
important in determining treatment for older breast cancer patients. This study aimed to identify the 
patient and tumor factors associated with treatment allocation in this population. 
Methods: Prospectively collected data on treatment received (surgery vs. PET) were analysed with 
multivariable logistic regression using the variables age, modified Charlson Comorbidity Index (CCI), 
Activities of Daily Living (ADL) score, Mini-Mental State Examination (MMSE) score, HER2 status, 
tumour size, grade and nodal status.  
Results: Data were available for 1122 cancers in 1098 patients recruited between April 2013 and 
May 2015 from 51 UK hospitals. Seventy-eight per cent of the population were treated surgically, 
with the remainder being treated with PET. Increasing patient age at diagnosis, increasing CCI score, 
large tumor size (five cm or more) and dependence in one or more ADL categories were all strongly 
associated with non-surgical treatment (p<0.05). 
Conclusions: Increasing comorbidity, large tumor size and reduced functional ability are associated 
with reduced likelihood of surgical treatment of breast cancer in older patients. However, age itself 
remains a significant factor for non-surgical treatment; reinforcing the need for evidence-based 
guidelines. 
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Introduction. 
A third of new breast cancer diagnoses occur in women age over 70 years in the UK 1. The number  
of women affected  will increase over time due to the ageing population 2. The prevalence of co-
morbidity and frailty increases with age, resulting  in deaths from other causes  exceeding  breast 
cancer mortality in older women with breast cancer 3,4. Additionally, tolerance of some breast cancer 
therapies is reduced in this age group 5,6. The majority (about 90%) of older women are diagnosed 
with oestrogen receptor (ER) positive disease 3.  Older patients with operable breast cancer may be 
offered alternative treatment modalities, such as primary endocrine therapy (PET) 7,8, where ER 
positive disease is treated with endocrine therapy alone without surgery. Non-operative 
management of older breast cancer patients accounts for up to 40% of treatment in the UK 9. 
Primary endocrine therapy gained popularity in the 1980s for the management of older women after 
tamoxifen was shown to be effective in this setting 10 and a succession of randomised controlled 
trials comparing its efficacy with surgery followed. A subsequent Cochrane review comparing PET 
with surgery in the over 70s demonstrated superior rates of local control with surgery but no 
difference in survival rates 11. However the studies included in the review were small and flawed by 
modern standards because tumor ER status was not always tested and the age range of the trials 
included relatively young older women with no documentation of health, fitness or frailty, in fact all 
patients were deemed fit for surgery under general anaesthesia and therefore frail patients were 
excluded.  A recent review of case series indicated that older frailer women tend to be treated with 
PET in routine practice and have inferior survival rates as would be expected due to higher other-
cause mortality 12. Since the trials included in the Cochrane review were conducted there have been 
significant increases in population life expectancy, so it is not clear that results of these trials are 
applicable in contemporary clinical practice. 
Recent reports have advocated the use of PET only in the very old or frail 13. Current national 
guidelines state that patients with operable breast cancer should be treated with surgery, and not 
PET, “irrespective of age” unless this is precluded by comorbidities 14; whilst the International 
Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA) 
recommend that PET should only be offered to patients with a “short estimated life expectancy (less 
than 2 to three years), who are considered unfit for surgery… or who refuse surgery” 15. However, as 
a large number of older women are treated with PET in UK and other countries it is not clear that 
this guidance is being followed consistently. 
Population cohort studies have been carried out to investigate the factors associated with non-
surgical treatment of breast cancer in older women and found that increasing age, comorbidities and 
worsening scores on Activities of Daily Living (ADL) were all associated with lower rates of surgery 16. 
An analysis of English cancer registry data showed that after adjusting for disease characteristics, age 
and comorbidity, there remained significant variation in the rate of PET use at the hospital level 17. 
This may reflect genuine variation in practice, which would contradict current recommendations. 
However, this analysis could not account for other potential confounding factors such as frailty and 
cognitive function, which would be expected to influence treatment decision making. There are also 
limitations concerning data quality such as missing data due to the retrospective and routine nature 
of data collection.  A further confounding factor is the influence of the patient’s preference for one 
or other option if they are given a choice. 
The study presented here aims to identify patient and tumor factors associated with treatment 
allocation in the older UK breast cancer population, including data on functional status, cognitive 
function and comorbidities, as well as disease characteristics. A planned interim analysis was 
undertaken using prospectively collected patient data from a large multicentre UK cohort study. 
 
  
Materials and Methods. 
Study Design. 
This study is part of a prospective observational cohort study of women aged over 70 years 
diagnosed with operable primary breast cancer in 51 UK breast cancer units between February 2013 
and June 2015. Recruitment for this trial is ongoing, and results presented here represent an interim 
analysis of the first 1451 patients. Data were collected on patient and tumor characteristics, and 
treatment type. Data collection time points for the study are at baseline (prior to any treatment 
being administered), six weeks post-treatment, six months post treatment, 12 months post-
treatment, 18 months post-treatment and 24 months post-treatment. Analyses are restricted to 
data collected up to six months post-treatment as the outcome of interest was primary treatment 
allocation.  
Analyses are also restricted to the subgroup of patients with operable ER positive disease at 
diagnosis. Variables used within the analysis are shown in table i. Patients with missing treatment 
data or with known ER negative disease were excluded from the analysis. Patients with missing ER 
status who did not receive endocrine therapy were assumed to be ER negative and also excluded 
from the analysis. Bilateral cancers are counted individually. Figure i shows the baseline features of 
the study population. 
 
Statistical Analysis. 
Primary treatment was dichotomised as “surgery” or “PET” according to whether or not the patient 
received surgery to the primary tumor. Simple logistic regression was used to investigate 
associations between complete covariates and treatment. The joint effect of patient level factors on 
the probability of surgical treatment was assessed using multivariable logistic regression.  
Variables with missing data cannot be included in standard regression models, but excluding cases 
with missing values (complete case analysis) can produce biased results where data is not missing 
completely at random, as well as reducing statistical precision. Missing data on disease 
characteristics and comorbidity was handled using the method of multiple imputation by chained 
equations (MICE) 18. Missing covariate values were imputed using predictive mean matching 19, and 
all variables included in the main analysis were incorporated into the imputation models. Twenty-
five completed datasets were used for subsequent analysis. Results of the regression models for 
each dataset were combined using the standard methods described by Rubin 20. Covariates with 
over 50% missing data were not included in the regression models. 
The performance of the regression model was assessed by considering the Receiver-Operating 
Characteristic (ROC) curve of the model, along with its corresponding area under the curve (AUC) 
statistic. This is a measure of the ability of the model to discriminate between individuals treated 
with surgery and PET21. The AUC can range from 0.5 to 1, where a value of 1 indicates perfect 
discrimination, and a value of 0.5 less indicates a model which performs no better than random 
chance. 
All analyses were conducted using the open source statistical programming language R (version 
3.0.1). Multiple imputation was implemented using the “mi” package (version 1.0). 
Ethics and Research Governance. 
The study protocols were approved by the UK National Research Ethics Committee (12/LO/1808) 
and institutional approvals were granted at each site. Written informed consent was obtained from 
the patient, or patient consultee in the case of patients with cognitive impairment.    
 
  
Results. 
Data were available on 1122 ER positive breast cancers in 1098 patients with a treatment record of 
either primary surgery with adjuvant therapy as deemed appropriate by the treating clinician 
(“surgery”) or endocrine therapy without surgery (“PET”). Characteristics of the study population can 
be seen in table i. 
Seventy-eight per cent of the study population were treated surgically, with the remainder being 
treated with PET. The patients treated with surgery were younger overall than those treated with 
PET (see table i). The imputation algorithm converged successfully, and exploratory analysis of the 
distributions of the imputed values did not raise concerns about their validity or plausibility.  
The multivariable logistic regression model is shown in Table ii. Increased age at diagnosis, increasing 
levels of comorbidity, large tumor size (five cm or more) and dependence in one or more ADL 
categories are all strongly associated with non-surgical treatment (Table ii). The ROC curve shows 
that the model discriminates well between individuals treated with PET and surgery, with the AUC 
statistic equal to 0.824 (95% CI, 0.792-0.855) (see Figure ii). 
  
Discussion. 
Of the 1122 ER positive operable breast cancers enrolled into the study to date, 78% were treated 
with surgery. Age was confirmed as one of the most important factors in determining treatment in 
older women with operable ER positive breast cancer, with increasing age associated with higher 
rates of PET, even accounting for other patient and disease characteristics. This is consistent with 
other studies 7,22,23 despite current UK guidelines, which state that patients should be treated with 
surgery and appropriate adjuvant therapy “irrespective of age” 14. 
Increasing age was associated with increasing rates of comorbidity and multi-morbidity 24, this in 
turn may reduce the survival benefit of more aggressive breast cancer therapies, such as surgery 4. It 
was therefore unsurprising that higher levels of co-morbidity in the study population are strongly 
associated with lower levels of surgical treatment, however this does not account for the effect seen 
with age. 
Functional dependence in one or more of the ADL categories was strongly associated with non-
surgical treatment in this study. Rates of functional dependence also increase with age and have 
been shown to affect treatment for in a small population of older breast cancer patients 22. 
Functional dependence has been associated with increased rates of post-operative complications 
and longer hospital stays in elderly cancer patients 25, possibly explaining why it has an impact on 
treatment allocation here. 
Additionally, large tumor size (five cm or more) was also associated with higher rates of PET. Tumors 
of this size usually mandate a mastectomy 26, and so these findings may represent patients and 
clinicians trying to avoid more major surgery. 
The rate of surgical treatment was higher in this study than some of the published figures for the UK, 
which range from 55-83% 8,16,27-30. This may result from a recruitment bias as patients within this 
study had to be recruited prior to commencing treatment, which was logistically more difficult with 
patients treated with PET as there is a shorter time period between diagnosis and treatment 
compared with surgery. Another possible bias could be that clinicians may be more likely to ‘follow 
the guidelines’ knowing that their data were being captured. This will ultimately result in an under-
representation of PET patients, and may explain why Lavelle and colleagues found a similar rate of 
83% having surgical treatment in their prospective cohort study 16.  
This study is limited by missing data, particularly with relation to ADL and MMSE, which is due, in 
part to patients opting out of completing the questionnaires. We have used multiple imputation to 
account for these missing data as it is less prone to bias than other commonly used methods to 
account for missing data. However, whilst exploratory analysis of the imputed data suggested that 
the values were plausible, it is not possible to verify the extent to which the distribution of the 
imputed data accurately represents that of the missing values. By using 25 imputations, uncertainty 
around the missing data is incorporated into the probabilities used to adjust for case mix which 
mitigates against any small biases due to problems with the imputation model.   
The findings of this study confirm existing research showing that age remains a significant predictor 
of non-surgical treatment after adjusting for disease characteristics and the underlying health status 
of the patient. However, it remains unclear as to whether or not current practice resulted in sub-
optimal outcomes. An attempt to compare outcomes under PET and surgery with adjuvant 
endocrine therapy using a randomised clinical trial failed due to lack of recruitment, which was 
explained by an unwillingness on behalf of both patients and clinicians to choose treatment at 
random 31. As a result, observational research is needed to investigate the effects of non-surgical 
treatment in this population. As recruitment and follow up of this cohort matures it will be possible 
to investigate the relationship between treatment, individual characteristics and outcomes such as 
survival and treatment failure. These data will be crucial in the development of evidence based 
guidance for patients and clinicians to help target treatments effectively. 
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